• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    1.235 -0.005 (-0.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lantern Pharma Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
    Via ACCESS Newswire
    News headline image
    Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
    From Lantern Pharma Inc.
    Via Business Wire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
    Via ACCESS Newswire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Lantern Pharma Earnings Preview ↗
     
    Via Benzinga
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
    Via ACCESS Newswire
    News headline image
    Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
    From Lantern Pharma Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.